KRAS and non-small cell lung carcinoma: It is worth mentioning that this study shows that Melittin can boost the anti-cancer effects of Erlotinib in NSCLC, potentially by affecting the JAK2–JAK3 pathway, which could be helpful even in KRAS-mutant cancers.